Macroscopic type is implicated in the prognostic impact of initial chemotherapy on peritoneal lavage cytology-positive gastric cancer with no other noncurative factors.
Gastric cancer
Initial chemotherapy
Initial surgery
Macroscopic type
Peritoneal lavage cytology
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
received:
21
10
2023
accepted:
19
02
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
aheadofprint
Résumé
Initial chemotherapy (Initial-C) followed by surgery is a promising treatment strategy for peritoneal lavage cytology-positive gastric cancer (CY1 GC) with no other noncurative factors. The aim of this study was to investigate the survival advantage of Initial-C compared to initial surgery (Initial-S) for this disease according to the macroscopic type, which was associated with prognosis and the efficacy of chemotherapy in GC. One hundred eighty-nine patients who were diagnosed with CY1 GC with no other noncurative factors at four institutions from January 2007 to December 2018 were enrolled. The patients were divided into a macroscopic type 4 group (N = 48) and a non-type 4 group (N = 141). The influence of initial treatment on overall survival (OS) in each group was evaluated. In the type 4 group, the 5-year OS rates of Initial-C (N = 35) and Initial-S (N = 13) were 11.6% and 0%, respectively (P = 0.801). The multivariate analysis could not show the survival advantage of Initial-C. In the non-type 4 group, the 5-year OS rates of Initial-C (N = 41) and Initial-S (N = 100) were 48.4% and 29.0%, respectively (P = 0.020). The multivariate analysis revealed that Initial-C was independently associated with prolonged OS (hazard ratio, 0.591; 95% confidence interval, 0.375-0.933: P = 0.023). Initial-C improves the prognosis of non-type 4 CY1 GC with no other noncurative factors. On the other hand, further development of effective chemotherapeutic regimens and innovative treatment strategies are required for type 4 CY1 GC.
Sections du résumé
BACKGROUND
BACKGROUND
Initial chemotherapy (Initial-C) followed by surgery is a promising treatment strategy for peritoneal lavage cytology-positive gastric cancer (CY1 GC) with no other noncurative factors. The aim of this study was to investigate the survival advantage of Initial-C compared to initial surgery (Initial-S) for this disease according to the macroscopic type, which was associated with prognosis and the efficacy of chemotherapy in GC.
METHODS
METHODS
One hundred eighty-nine patients who were diagnosed with CY1 GC with no other noncurative factors at four institutions from January 2007 to December 2018 were enrolled. The patients were divided into a macroscopic type 4 group (N = 48) and a non-type 4 group (N = 141). The influence of initial treatment on overall survival (OS) in each group was evaluated.
RESULTS
RESULTS
In the type 4 group, the 5-year OS rates of Initial-C (N = 35) and Initial-S (N = 13) were 11.6% and 0%, respectively (P = 0.801). The multivariate analysis could not show the survival advantage of Initial-C. In the non-type 4 group, the 5-year OS rates of Initial-C (N = 41) and Initial-S (N = 100) were 48.4% and 29.0%, respectively (P = 0.020). The multivariate analysis revealed that Initial-C was independently associated with prolonged OS (hazard ratio, 0.591; 95% confidence interval, 0.375-0.933: P = 0.023).
CONCLUSIONS
CONCLUSIONS
Initial-C improves the prognosis of non-type 4 CY1 GC with no other noncurative factors. On the other hand, further development of effective chemotherapeutic regimens and innovative treatment strategies are required for type 4 CY1 GC.
Identifiants
pubmed: 38512543
doi: 10.1007/s10147-024-02496-1
pii: 10.1007/s10147-024-02496-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : KAKENHI
ID : JP22K16483
Informations de copyright
© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Brierley JD, Gospodarowicz MK, Wittekind C (2017) International union against cancer (UICC) TNM classification of malignant tumours, 8th edn. John Wiley & Sons, Hoboken
Amin MB, Edge SB, Greene FL et al (2017) AJCC cancer staging manual, 8th edn. Springer, New York
Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–12
doi: 10.1007/s10120-011-0041-5
Jamel S, Markar SR, Malietzis G et al (2018) Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer 21:10–18
doi: 10.1007/s10120-017-0749-y
pubmed: 28779261
Ajani JA, D’Amico TA, Bentrem DJ et al (2022) Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:167–92
doi: 10.6004/jnccn.2022.0008
pubmed: 35130500
Lordick F, Carneiro F, Cascinu S et al (2022) ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1005–1020
doi: 10.1016/j.annonc.2022.07.004
pubmed: 35914639
Kodera Y, Ito S, Mochizuki Y et al (2012) Long term follow up of patients who were positive for peritoneal lavage cytology:fnal report from the CCOG0301 study. Gastric Cancer 15:335–337
doi: 10.1007/s10120-012-0156-3
pubmed: 22527184
Kano Y, Ichikawa H, Hanyu T et al (2022) Conversion surgery for stage IV gastric cancer: a multicenter retrospective study. BMC Surg 14(22):428
doi: 10.1186/s12893-022-01874-8
Solaini L, Ministrini S, Bencivenga M et al (2019) Conversion gastrectomy for stage IV unresectable gastric cancer: a IRCG retrospective cohort study. Gastric Cancer 22:1285–1293
doi: 10.1007/s10120-019-00968-2
pubmed: 31065878
Yoshida K, Yasufuku I, Terashima M et al (2021) CONVO-GC-1 study group, federation of Asian clinical oncology (FACO). International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 6:227–40
doi: 10.1002/ags3.12515
pubmed: 35261948
pmcid: 8889854
Yamaguchi K, Yoshida K, Tanahashi T et al (2018) The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer 21:315–323
doi: 10.1007/s10120-017-0738-1
pubmed: 28616743
Yasufuku I, Nunobe S, Ida S et al (2020) Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Gastric Cancer 23:319–327
doi: 10.1007/s10120-019-00994-0
pubmed: 31350702
Aizawa M, Nashimoto A, Yabusaki H et al (2015) The clinical significance of potentially curative resection for gastric cancer following the clearance of free cancer cells in the peritoneal cavity by induction chemotherapy. Surg Today 45:611–617
doi: 10.1007/s00595-014-0979-0
pubmed: 25027056
Nakamura M, Ojima T, Nakamori M et al (2019) Conversion surgery for gastric cancer with peritoneal metastasis based on the diagnosis of second-look staging laparoscopy. J Gastrointest Surg 23:1758–1766
doi: 10.1007/s11605-018-3983-7
pubmed: 30264385
Yamaguchi T, Takashima A, Nagashima K et al (2021) Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study. Gastric Cancer 24:701–709
doi: 10.1007/s10120-020-01137-6
pubmed: 33179192
Bollschweiler E, Boettcher K, Hoelscher AH et al (1993) Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer 71:2918–2925
doi: 10.1002/1097-0142(19930515)71:10<2918::AID-CNCR2820711006>3.0.CO;2-V
pubmed: 8490819
Blackham AU, Swords DS, Levine EA et al (2016) Is linitis plastica a contraindication for surgical resection: a multi-institution study of the U.S. Gastric cancer collaborative. Ann Surg Oncol 23:1203–11
doi: 10.1245/s10434-015-4947-8
pubmed: 26530447
An JY, Kang TH, Choi MG et al (2008) Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg 12:1364–1369
doi: 10.1007/s11605-008-0516-9
pubmed: 18516653
Song XH, Zhang WH, Kai Liu et al (2020) Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China. World J Surg Oncol 18:204
doi: 10.1186/s12957-020-01987-5
pubmed: 32792016
pmcid: 7427284
Eba J, Nakamura K (2022) Overview of the ethical guidelines for medical and biological research involving human subjects in Japan. Jpn J Clin Oncol 52:539–544
doi: 10.1093/jjco/hyac034
pubmed: 35349681
pmcid: 9157286
Japanese Gastric Cancer Association (2021) Japanese gastric cancer treatment guidelines 2018. Gastric Cancer 24:1–21
doi: 10.1007/s10120-020-01042-y
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Smyth EC, Nilsson M, Grabsch HI et al (2020) Gastric cancer. Lancet 396:635–648
doi: 10.1016/S0140-6736(20)31288-5
pubmed: 32861308
Piessen G, Messager M, Leteurtre E et al (2009) Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 250:878–887
doi: 10.1097/SLA.0b013e3181b21c7b
pubmed: 19855261
Heger U, Blank S, Wiecha C et al (2014) Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol 21:1739–1748
doi: 10.1245/s10434-013-3462-z
pubmed: 24419755
Koseki Y, Hatakeyama K, Terashima M et al (2023) Molecular profile of poorly cohesive gastric carcinoma with special reference to survival. Gastric Cancer 26:553–64
doi: 10.1007/s10120-023-01390-5
pubmed: 37036539
Fukagawa T, Katai H, Saka M et al (2010) Significance of lavage cytology in advanced gastric cancer patients. World J Surg 34:563–568
doi: 10.1007/s00268-009-0355-1
pubmed: 20054543
Endo S, Ikenaga M, Ohta K et al (2019) Prognostic factors for cytology-positive gastric cancer. Surg Today 49:56–64
doi: 10.1007/s00595-018-1704-1
pubmed: 30167924
Kano K, Aoyama T, Maezawa Y et al (2017) The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy. Int J Clin Oncol 22:887–896
doi: 10.1007/s10147-017-1128-8
pubmed: 28456896
Yago A, Haruta S, Ueno M et al (2022) Clinical significance of initial treatment for peritoneal lavage cytology-positive gastric cancer: outcomes according to treatment strategy. World J Surg Oncol 20:35
doi: 10.1186/s12957-022-02512-6
pubmed: 35168610
pmcid: 8848799
Kuramoto M, Shimada S, Ikeshima S et al (2009) Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 250:242–246
doi: 10.1097/SLA.0b013e3181b0c80e
pubmed: 19638909
Yamaguchi T, Takashima A, Nagashima K et al (2020) Efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): a multicenter retrospective study. Ann Surg Oncol 27:284–292
doi: 10.1245/s10434-019-07697-x
pubmed: 31535301
Iwasaki Y, Terashima M, Mizusawa J et al (2021) Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer 24:492–502
doi: 10.1007/s10120-020-01136-7
pubmed: 33200303
Chen GM, Yuan SQ, Nie RC et al (2020) Surgical outcome and long-term survival of conversion surgery for advanced gastric cancer. Ann Surg Oncol 27:4250–4260
doi: 10.1245/s10434-020-08559-7
pubmed: 32506192
Lee JH, Son SY, Lee CM et al (2014) Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy. Gastric Cancer 17:529–536
doi: 10.1007/s10120-013-0306-2
pubmed: 24101155
Ishigami H, Fujiwara Y, Fukushima R et al (2018) Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol 36:1922–1929
doi: 10.1200/JCO.2018.77.8613
pubmed: 29746229
Ishigami H, Tsuji Y, Shinohara H et al (2021) Intraperitoneal chemotherapy as adjuvant or perioperative chemotherapy for patients with type 4 scirrhous gastric cancer: PHOENIX-GC2 trial. J Clin Med 10:5666
doi: 10.3390/jcm10235666
pubmed: 34884367
pmcid: 8658657